COPD Diagnostic/Prognostic Test
Chronic Obstructive Pulmonary Disease (COPD)
Key Facts
About Oxford Cancer Analytics
Oxford Cancer Analytics is a private, pre-revenue diagnostics company founded in 2016 and based in Oxford, UK. It is developing a proprietary platform that combines high-throughput proteomic analysis of blood samples with advanced machine learning to generate diagnostic and prognostic insights for lung diseases, starting with COPD. The company's mission is to transform fragmented and slow diagnostic pathways by providing scalable, biologically grounded tools that enable earlier intervention and more consistent clinical decision-making. Led by a team with expertise in diagnostics, AI, and clinical medicine, OXcan represents a convergence of proteomics and computational biology aimed at a significant global health burden.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR0200 | Pulmatrix | Preclinical |
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| AN01 | AirNexis Therapeutics | Phase 2 |
| SMS Cell Therapy | SMSbiotech | Phase 1b |
| dNerva Lung Denervation System / Targeted Lung Denervation (TLD) | Nuvaira | Phase 3 |
| LBP for COPD | Alveolus Bio | Preclinical |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |